



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Data Sheet

CD47 CRISPR/Cas9 Lentivirus (Non-Integrating)

Catalog #: 78063

Description

CD47 (also known as Rh-associated protein, GP42, Integrin-Associated Protein (IAP), or Neurophilin) is an immunoglobulin-like protein that interacts with its receptor, Signal-regulatory protein alpha (SIRP α), on macrophages. This binding interaction regulates transmigration, oxidative burst cytokine production, and phagocytosis, generating a “don’t eat me” signal. CD47 is ubiquitously expressed on the surface of normal cells, but is overexpressed in numerous cancer cells where it is thought to contribute to the resistance of tumors to phagocyte-dependent clearance.

The CD47 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human CD47 (NM_198793.2) driven by a U6 promoter (Figures 1 and 2).

Note: unlike human CD47 CRISPR/Cas9 Lentivirus (Integrating) (BPS Bioscience, #78056), the human CD47 CRISPR/Cas9 Lentivirus (Non-Integrating) is made with a mutated Integrase, resulting in only transient expression of the Cas9 and CD47 targeting sgRNA. While this may minimize potential off-targeting risks due to either prolonged expression or integration of the Cas9, puromycin selection should not be used for more than 48 hours post-transduction, which may lower knockout efficiency.

Application

1. Transient knock-down of CD47 in a target cell pool.
2. Generation of a stable CD47 knock-out cell line following limited dilution.

Formulation

The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.

Titer

Two vials (500 μ l x 2) of lentivirus at a titer $\geq 1 \times 10^6$ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com




Figure 1. Schematic of the Lenti-vector used to generate the CD47 CRISPR/Cas9 Lentivirus.

Gene Target:	Primer ID:	sgRNA Sequence:
CD47	CD47-1	ATCGAGCTAAAATATCGTGT
CD47	CD47-2	GCACTTAAATATAGATCCGG
CD47	CD47-3	AGTGATGCTGTCTCACACAC
CD47	CD47-4	TTTGCACTACTAAAGTCAGT

Figure 2. List of sgRNA Sequences in the CD47 CRISPR/Cas9 Lentivirus.

Storage

Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Biosafety

None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells. Although the pseudotyped lentiviruses are replication-incompetent, they do require the use of a Biosafety Level 2 facility. BPS recommends following all federal, state, local, and institutional regulations and using all appropriate safety precautions.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com




Figure 3. Knock-down of CD47 in CD47 Over-Expressing HEK293 cells.

CD47 Over-expressing HEK293 cells (BPS Bioscience, #71249) were transduced via spinoculation with 5,000,000 TU/well of CD47 CRISPR/Cas9 lentivirus. 72 hours after transduction, cells were stained with PE anti-human CD47 antibody (BioLegend, #323108) and analyzed by FACS. Parental CD47 Over-expressing HEK293 cells are shown in green, and the transduced cells are shown in blue.

Related Products

<u>Product</u>	<u>Cat. #</u>	<u>Size</u>
CD47 CRISPR/Cas9 Lentivirus (Integrating)	78056	500 µl x 2
TCR CRISPR/Cas9 Lentivirus (Integrating)	78055	500 µl x 2
TCR CRISPR/Cas9 Lentivirus (Non-Integrating)	78062	500 µl x 2
Cas9, His-tag (<i>S. pyogenes</i>)	100206-1	50 µg
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line	79887	2 vials
CD47 - HEK293 Cell Line	71249	2 vials
Anti-CD47 Antagonist Antibody	79065-1	50 µg
SIRP-α / HEK293 Recombinant Cell Line	60689	2 vials

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com